{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T08:10:20Z","timestamp":1733472620923,"version":"3.30.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.jpba.2024.116580","type":"journal-article","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T20:46:55Z","timestamp":1732308415000},"page":"116580","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Determination of sacubitril and seven sartan drugs in serum samples by online solid phase extraction-liquid chromatography-tandem mass spectrometry"],"prefix":"10.1016","volume":"254","author":[{"given":"Yanan","family":"Guo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Geng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juanjuan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2024.116580_bib1","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/clc.23303","article-title":"Hypertension in older adults: assessment, management, and challenges","volume":"43","author":"Oliveros","year":"2020","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.jpba.2024.116580_bib2","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1161\/hc4601.099404","article-title":"Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type 1 receptor blockade with valsartan in the improvement of inflammation-induced vascular injury","volume":"104","author":"Wu","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.jpba.2024.116580_bib3","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1097\/HJH.0b013e32834494f6","article-title":"Interactive effect of angiotensin II type 1 receptor (AGT1R) polymorphisms and plasma irbesartan concentration on antihypertensive therapeutic responses to irbesartan","volume":"29","author":"Jiang","year":"2011","journal-title":"J. Hypertens."},{"key":"10.1016\/j.jpba.2024.116580_bib4","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.2165\/00003495-200262080-00016","article-title":"Candesartan cilexetil - an update of its use in essential hypertension","volume":"62","author":"Easthope","year":"2002","journal-title":"Drugs"},{"key":"10.1016\/j.jpba.2024.116580_bib5","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2165\/00003495-199754020-00009","article-title":"Valsartan - a review of its pharmacology and therapeutic use in essential hypertension","volume":"54","author":"Markham","year":"1997","journal-title":"Drugs"},{"key":"10.1016\/j.jpba.2024.116580_bib6","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.2165\/00003495-200868110-00008","article-title":"Irbesartan: a review of its use in hypertension and diabetic nephropathy","volume":"68","author":"Croom","year":"2008","journal-title":"Drugs"},{"key":"10.1016\/j.jpba.2024.116580_bib7","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.2165\/00003495-200666140-00011","article-title":"Valsartan\/hydrochlorothiazide - a review of its use in the management of hypertension","volume":"66","author":"Wagstaff","year":"2006","journal-title":"Drugs"},{"key":"10.1016\/j.jpba.2024.116580_bib8","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jamainternmed.2015.7661","article-title":"Sacubitril-Valsartan for the treatment of heart failure: effectiveness and value","volume":"176","author":"Ollendorf","year":"2016","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.jpba.2024.116580_bib9","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1586\/17512433.2016.1153423","article-title":"Combining angiotensin II receptor 1 antagonism and neprilysin inhibition for the treatment of heart failure","volume":"9","author":"Katsanos","year":"2016","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"10.1016\/j.jpba.2024.116580_bib10","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ijcard.2022.09.050","article-title":"Effectiveness and safety evaluation of sacubitril\/valsartan in blood pressure control and clinical outcomes for elderly patients with heart failure and hypertension: a prospective cohort study","volume":"371","author":"Li","year":"2023","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.jpba.2024.116580_bib11","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1253\/circj.CJ-23-0349","article-title":"Efficacy and safety of Sacubitril\/Valsartan in Japanese patients with heart failure according to baseline systolic blood pressure - results from a subgroup analysis of the PARALLEL-HF study","volume":"88","author":"Tsutsui","year":"2023","journal-title":"Circ. J."},{"key":"10.1016\/j.jpba.2024.116580_bib12","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/j.jacc.2020.02.009","article-title":"Systolic blood pressure in heart failure with preserved ejection fraction treated with Sacubitril\/Valsartan","volume":"75","author":"Selvaraj","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.jpba.2024.116580_bib13","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s40265-016-0544-9","article-title":"Sacubitril\/Valsartan: a review in chronic heart failure with reduced ejection fraction","volume":"76","author":"McCormack","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.jpba.2024.116580_bib14","doi-asserted-by":"crossref","DOI":"10.1007\/s10557-023-07509-1","article-title":"The effects of Sacubitril\/Valsartan compared to olmesartan on the blood pressure and glucolipid metabolism in DM patients with primary hypertension","author":"Zhang","year":"2023","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.jpba.2024.116580_bib15","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1093\/eurheartj\/ehw570","article-title":"Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril\/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF","volume":"38","author":"B\u00f6hm","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.jpba.2024.116580_bib16","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3390\/ph13020032","article-title":"Gr\u0430di\u0435nt HPLC m\u0435th\u043ed f\u043er simult\u0430n\u0435\u043eus d\u0435t\u0435rmin\u0430ti\u043en \u043ef \u0435ight s\u0430rt\u0430n \u0430nd st\u0430tin drugs in th\u0435ir pur\u0435 \u0430nd d\u043es\u0430g\u0435 f\u043erms","volume":"13","author":"Z\u0430r\u0435h","year":"2020","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.jpba.2024.116580_bib17","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jchromb.2005.12.035","article-title":"Rapid determination of valsartan in human plasma by protein precipitation and high-performance liquid chromatography","volume":"832","author":"Macek","year":"2006","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2024.116580_bib18","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1007\/s12272-014-0449-7","article-title":"Determination of the R-enantiomer of valsartan in pharmaceutical formulation by capillary electrophoresis","volume":"38","author":"Lee","year":"2015","journal-title":"Arch. Pharmacal Res"},{"key":"10.1016\/j.jpba.2024.116580_bib19","first-page":"368","article-title":"Simultaneous determination of valsartan, amlodipine besylate and hydrochlorothiazide using capillary zone electrophoresis (CZE)","volume":"70","author":"Ebeid","year":"2015","journal-title":"Die Pharm."},{"key":"10.1016\/j.jpba.2024.116580_bib20","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/j.jpba.2006.12.030","article-title":"Development and validation of a method for quantitative determination of valsartan in human plasma by liquid chromatography-tandem mass spectrometry","volume":"43","author":"Koseki","year":"2007","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116580_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115829","article-title":"Development and validation of a sensitive and simple LC-MS\/MS method for simultaneous quantitation of valsartan, sacubitril and sacubitrilat in pediatric population","volume":"238","author":"Yang","year":"2024","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116580_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics10040221","article-title":"A review on liquid chromatography-tandem mass spectrometry methods for rapid quantification of oncology drugs","volume":"10","author":"Wong","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jpba.2024.116580_bib23","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/chromsci\/bmac059","article-title":"A multi-analyte LC\u2013MS\/MS method for determination and quantification of six nitrosamine impurities in sartans like Azilsartan, Valsartan, Telmisartan, Olmesartan, Losartan and Irbesartan","volume":"62","author":"Gopireddy","year":"2024","journal-title":"J. Chromatogr. Sci."},{"key":"10.1016\/j.jpba.2024.116580_bib24","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.jfda.2015.02.008","article-title":"New ultra-performance liquid chromatography-tandem mass spectrometry method for the determination of irbesartan in human plasma","volume":"23","author":"Wani","year":"2015","journal-title":"J. Food Drug Anal."},{"key":"10.1016\/j.jpba.2024.116580_bib25","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jchromb.2015.07.047","article-title":"Development, validation and application of the liquid chromatography tandem mass spectrometry method for simultaneous quantification of azilsartan medoxomil (TAK-491), azilsartan (TAK-536), and its 2 metabolites in human plasma","volume":"1001","author":"Kuze","year":"2015","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2024.116580_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2021.122608","article-title":"Determination of 13 antidepressants in blood by UPLC-MS\/MS with supported liquid extraction pretreatment","volume":"1171","author":"Ma","year":"2021","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2024.116580_bib27","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/jssc.201800785","article-title":"Application of solid-phase microextraction in current biomedical research","volume":"42","author":"Roszkowska","year":"2019","journal-title":"J. Sep. Sci."},{"key":"10.1016\/j.jpba.2024.116580_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115281","article-title":"Liquid chromatography-tandem mass spectrometry analysis of delamanid and its metabolite in human cerebrospinal fluid using protein precipitation and on-line solid-phase extraction","volume":"227","author":"Mazanhanga","year":"2023","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116580_bib29","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jpba.2013.05.006","article-title":"On-line solid phase extraction-liquid chromatography, with emphasis on modern bioanalysis and miniaturized systems","volume":"87","author":"Rogeberg","year":"2014","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116580_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.envpol.2021.118235","article-title":"Fluorescent whitening agents in Baiyangdian Lake in North China: analysis, occurrence, distribution and ecological risk assessment","volume":"291","author":"Wu","year":"2021","journal-title":"Environ. Pollut."},{"key":"10.1016\/j.jpba.2024.116580_bib31","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.forsciint.2016.07.004","article-title":"Targeted toxicological screening for acidic, neutral and basic substances in postmortem and antemortem whole blood using simple protein precipitation and UPLC-HR-TOF-MS","volume":"266","author":"Telving","year":"2016","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.jpba.2024.116580_bib32","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s11094-024-03171-5","article-title":"Development and validation of a method for quantification of Lisinopril, Indapamide, Metoprolol, Valsartan, and Amoldipine in human blood serum by HPLC-MS\/MS","volume":"58","author":"Mylnikov","year":"2024","journal-title":"Pharm. Chem. J."},{"key":"10.1016\/j.jpba.2024.116580_bib33","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1134\/S1061934823080063","article-title":"Profiling detection and validation of six sartan substances in human urine by LC-MS\/MS","volume":"78","author":"Hong","year":"2023","journal-title":"J. Anal. Chem."},{"key":"10.1016\/j.jpba.2024.116580_bib34","first-page":"622","article-title":"Simultaneous determination of three components of sacubitril\/valsartan in human plasma by HPLC-FD and its application (in Chinese)","volume":"39","author":"Ma","year":"2022","journal-title":"Chin. J. Mod. Appl. Pharm."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708524006228?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708524006228?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T07:43:31Z","timestamp":1733471011000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708524006228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":34,"alternative-id":["S0731708524006228"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2024.116580","relation":{},"ISSN":["0731-7085"],"issn-type":[{"type":"print","value":"0731-7085"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Determination of sacubitril and seven sartan drugs in serum samples by online solid phase extraction-liquid chromatography-tandem mass spectrometry","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2024.116580","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"116580"}}